在HFrEF患者中对AZD3427,一种新型放松素受体激动剂进行透的第1b期研究
Marcin Ufnal1, Macarena P Quintana-Hayashi1, Kathleen Connolly1
1Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Stockholm, Sweden.
ESC heart failure
|September 4, 2025
概括
这项研究研究了AZD3427
科学领域:
- 心脏病学
- 肝脏病学
- 药理学
背景情况:
- 心力衰竭 (HF) 和功能障碍经常同时存在,使患者的结果恶化.
- 人们迫切需要治疗心脏和功能障碍.
- AZD3427,是一种放松类型,已显示出改善HF患者的心脏输出和功能的潜力.
研究的目的:
- 评估AZD3427对心力衰竭患者的透效应,心力衰竭患者的排泄率 (HFrEF) 和估计透率 (eGFR) 的降低.
- 通过改善脏血流和皮质体积,探索AZD3427可能增强质过率 (GFR) 的机制.
主要方法:
- 这项Re-PERFUSE研究是一项随机,双盲,安慰剂对照的第1b期试验.
- 患有HFrEF和eGFR的患者接受AZD3427单剂量或安慰剂.
- 使用 [15O] 标记的水测量了治疗前和治疗后的皮血流量.
主要成果:
- 该研究旨在评估皮质血流的变化,区分全球和焦点变化.
- 它旨在提供潜在的脏招募和增加过膜面积的见解.
- 将监测AZD3427的安全性和耐受性.
结论:
- 这项研究将评估AZD3427的双重心脏和功能.
- 这些发现可以为未来的治疗策略提供指导,用于治疗并发性HF和功能障碍.
- 为了确认AZD3427的益处,正在进行进一步的研究.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure II: Pathophysiology
33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483


